Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangdong Marubi Biotechnology CoSHSE:603983 +2.15%84 ROC (Joel Greenblatt) % is 25.49% as of Jun. 2026, which is 72% below its 10-year median of 92.19. GuruFocus rates SHSE:603983 with a GF Score™ of 84/100 and a GF Value™ of ¥45.75 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,985 Consumer Packaged Goods companies, Guangdong Marubi Biotechnology Co ranks better than 75.62% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Guangdong Marubi Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 25.49%.
The historical rank and industry rank for Guangdong Marubi Biotechnology Co's ROC (Joel Greenblatt) % or its related term are showing as below:
SHSE:603983'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.12 Med: 92.19 Max: 241
Current: 26.12
During the past 13 years, Guangdong Marubi Biotechnology Co's highest ROC (Joel Greenblatt) % was 241.00%. The lowest was 26.12%. And the median was 92.19%.
SHSE:603983's ROC (Joel Greenblatt) % is ranked better than 75.62% of 1985
companies
in the Consumer Packaged Goods industry
Industry Median: 11.99
vs SHSE:603983: 26.12
Guangdong Marubi Biotechnology Co (SHSE:603983) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangdong Marubi Biotechnology Co ROC (Joel Greenblatt) % Chart
SHSE:603983 vs PG, CL, EL: ROC (Joel Greenblatt) % Comparison
For the Household & Personal Products subindustry, Guangdong Marubi Biotechnology Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangdong Marubi Biotechnology Co ROC (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Guangdong Marubi Biotechnology Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Guangdong Marubi Biotechnology Co's ROC (Joel Greenblatt) % falls into.
Guangdong Marubi Biotechnology Co ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 25.49% mean?
Guangdong Marubi Biotechnology Co (SHSE:603983) has a ROC (Joel Greenblatt) % of 25.49% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Guangdong Marubi Biotechnology Co and its competitors. This is 72% below median its historical median of 92.19. Over the past decade, Guangdong Marubi Biotechnology Co's ROC (Joel Greenblatt) % has ranged from 26.12 to 241.00. According to the industry distribution chart, Guangdong Marubi Biotechnology Co ranks #484 out of 1985 companies in the Consumer Packaged Goods industry, placing it in the top 24.4%.
Is Guangdong Marubi Biotechnology Co's ROC (Joel Greenblatt) % too high?
Guangdong Marubi Biotechnology Co's current ROC (Joel Greenblatt) % of 25.49% is 72% below median its 10-year median of 92.19. Over the past 10 years, this metric has ranged from a low of 26.12 to a high of 241.00. The Consumer Packaged Goods industry median ROC (Joel Greenblatt) % is 11.99. Guangdong Marubi Biotechnology Co's value of 25.49% is 112.6% above this industry median. Based on the distribution chart, Guangdong Marubi Biotechnology Co ranks #484 out of 1985 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Guangdong Marubi Biotechnology Co has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangdong Marubi Biotechnology Co's ROC (Joel Greenblatt) % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Guangdong Marubi Biotechnology Co ranks #484 out of 1985 companies for ROC (Joel Greenblatt) %. This places Guangdong Marubi Biotechnology Co in the top 24% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.99. Guangdong Marubi Biotechnology Co's value of 25.49% is 112.6% above this benchmark. Historically, Guangdong Marubi Biotechnology Co's own ROC (Joel Greenblatt) % has ranged from 26.12 to 241.00 over the past decade. While the company's 10-year median is 92.19 vs. the industry median of 11.99, Guangdong Marubi Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median ROC (Joel Greenblatt) % among Consumer Packaged Goods companies is 11.99, based on 1,985 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangdong Marubi Biotechnology Co's current ROC (Joel Greenblatt) % of 25.49% is 112.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Guangdong Marubi Biotechnology Co and its competitors. For the Consumer Packaged Goods industry, the median ROC (Joel Greenblatt) % is 11.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangdong Marubi Biotechnology Co's current ROC (Joel Greenblatt) % is 25.49%, which is 72% below median its own 10-year median of 92.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangdong Marubi Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Guangdong Marubi Biotechnology Co (SHSE:603983) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥45.75, compared to a current price of ¥28.55 — trading 37.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is 25.49%, which is 72% below median its 10-year median of 92.19 and 112.6% above the Consumer Packaged Goods industry median of 11.99. Guangdong Marubi Biotechnology Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Guangdong Marubi Biotechnology Co (SHSE:603983), the current ROC (Joel Greenblatt) % is 25.49% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangdong Marubi Biotechnology Co (SHSE:603983) Overvalued in 2026?
Based on GuruFocus' analysis, Guangdong Marubi Biotechnology Co stock appears to be undervalued.
The current stock price of ¥28.55 is trading 37.6% below its estimated GF Value™ of ¥45.75.
GuruFocus considers Guangdong Marubi Biotechnology Co to be Significantly Undervalued.
Key valuation signals for SHSE:603983:
ROC (Joel Greenblatt) %: 25.49% (72% below median its 10-year median of 92.19)
GF Value™: ¥45.75 vs. price of ¥28.55 (37.6% below fair value)
Industry Position: 112.6% above the Consumer Packaged Goods median (#484 of 1985)
No single metric tells the full story. See the SHSE:603983 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603983 has been successfully added to your 
